3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 1/2
2
Phase 2/3
1
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other
1
Conditions
Polycystic Ovary Syndrome
1
Obesity
1
Fatty Liver
1
Interventions
Paclitaxel
9
Magnetic Resonance Spectroscopy
8
Cyclophosphamide
8
Cisplatin
8
Carboplatin
8
Granulocyte Colony-Stimulating Factor
7
Etoposide
7
Radiotherapy, Intensity-Modulated
6
Nivolumab
6
Leucovorin
6
Filgrastim
6
Drug Therapy
6
Doxorubicin
6
Radiotherapy
5
Oxaliplatin
5
Fluorouracil
5
Docetaxel
5
Bevacizumab
5
pembrolizumab
4
gallium 68 PSMA-11
4
Taxes
4
Sirolimus
4
Rituximab
4
Pemetrexed
4
Melphalan
4
Immunoglobulin G
4
Gemcitabine
4
Disulfides
4
Dexamethasone
4
Cytarabine
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Has results
×
Exenatide
×
Clear all
NCT02157974
2024-06-04
APPLE
University of Colorado, Denver
Phase 2/3
Completed
92 enrolled
17 charts